Blue Scorpion touts venom-based homeopathic pain relief with FDA NDC listing

Blue Scorpion is drawing attention this summer with a Caribbean Blue Scorpion venom formula that the brand says offers non-opioid relief for pain, inflammation and related symptoms. The product carries dual FDA National Drug Code listings and is aimed at consumers, athletes and holistic practitioners seeking an alternative to conventional analgesics.

Why it matters: - Blue Scorpion is positioning a venom-based homeopathic product as a non-opioid option for people seeking pain and inflammation relief. - The formula’s dual FDA National Drug Code listing gives the product a regulatory marker that many wellness supplements do not have. - The brand is targeting health-conscious adults, athletes and holistic practitioners as demand rises for natural pain management alternatives.

What happened: - Blue Scorpion is promoting its flagship homeopathic formula this summer. - The product uses Heteroctenus Princeps venom sourced from the Caribbean. - The formula carries FDA National Drug Code listings 83627-901-01 and 83627-901-02. - The product is sold as an oral drop.

The details: - Blue Scorpion says the formula is designed to address nerve pain, joint stiffness, body aches, bruising, digestive discomfort and restless sleep. - The brand says its patented polarization process activates peptide compounds in the venom at a homeopathic micro-dose. - The formula also includes Apis Mellifica and Rhus Toxicodendron. - Blue Scorpion describes the product as alcohol-free and dependency-free. - The company says the product is produced to homeopathic pharmacopoeia standards. - The product is available directly through the brand’s website. - The website offers ingredient details, NDC documentation and verified customer experiences.

Between the lines: - Blue Scorpion is trying to stand out in a crowded natural pain relief market by pairing a rare ingredient with FDA registration. - The company is leaning on interest in scorpion venom research and peer-reviewed work on venom-derived peptides. - The athlete-focused pitch suggests the brand sees recovery and travel convenience as a key sales driver. - The company’s claims about multi-symptom relief and systemic effects are marketing claims, not independently verified findings in the release.

What’s next: - Blue Scorpion expects summer demand to expand among fitness-focused communities. - The company is likely to keep emphasizing its NDC listing, ingredient provenance and non-opioid positioning as it markets the product. - Consumers researching the formula can review the brand’s documentation and purchase through its website.

The bottom line: - Blue Scorpion is betting that a rare venom-based homeopathic formula with FDA NDC registration will resonate with buyers looking for a natural, non-opioid pain relief option.